Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 2/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812079 | 0.77 | FDPS (0.50) | LAP3FDPS | |
| SCHEMBL3805257 | 0.73 | FDPS (0.54) | LAP3FDPS | |
| SCHEMBL4821020 | 0.72 | — | — | |
| SCHEMBL17063212 | 0.71 | FDPS (0.38) | LAP3FDPS | |
| Phosphine SCHEMBL27341953 | 0.71 | FDPS (0.53) | LAP3FDPS | |
| SCHEMBL7752112 | 0.69 | FOLH1 (0.50) | — | |
| SCHEMBL5858062 | 0.69 | ANPEP (0.35) | FDPS | |
| Ammonia Solution, Strong SCHEMBL19520721 | 0.69 | BBOX1 (0.31) | BBOX1 | |
| SCHEMBL25197140 | 0.69 | — | — | |
| SCHEMBL1011790 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373433-B1 | CUBIC LIQUID CRYSTALLINE PHASE PRECURSOR | CHILDRENS HOSP MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1682091-B1 | COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES | CAMURUS AB (SE) | 2017-03-29 | — | — | EP | disclosed |
| US-9522377-B2 | Method for improving the properties of amphiphile particles | CAMURUS AB (SE) | 2016-12-20 | — | — | US | disclosed |
| US-9067190-B2 | Method for loading amphiphile particles with active agents | CAMURUS AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-8865021-B2 | Compositions of lipids and cationic peptides | CAMURUS AB (SE) | 2014-10-21 | — | — | US | disclosed |
| EP-1670436-B1 | COMPOSITION COMPRISING ETHER LIPID | CAMURUS AB (SE) | 2013-11-20 | — | — | EP | disclosed |
| EP-1660227-B1 | METHOD FOR IMPROVING THE PROPERTIES OF AMPHIPHILE PARTICLES | CAMURUS AB (SE) | 2012-05-23 | — | — | EP | disclosed |
| EP-1663468-B1 | METHOD FOR LOADING AMPHIPHILE PARTICLES WITH ACTIVE AGENTS | CAMURUS AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070231374-A1 | Composition Comprising Ether Lipid | CAMURUS AB (SE) | 2007-10-04 | — | — | US | disclosed |
| US-20070134336-A1 | Method for improving the properties of amphiphile particles | CAMURUS AB (SE) | 2007-06-14 | — | — | US | disclosed |
| US-20070110777-A1 | Method for loading amphiphile particles with active agents | CAMURUS AB (SE) | 2007-05-17 | — | — | US | disclosed |
| US-20070080323-A1 | Compositions of lipids and cationic peptieds | CAMURUS AB (SE) | 2007-04-12 | — | — | US | disclosed |
| EP-1682091-A1 | COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES | CAMURUS AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1670436-A2 | COMPOSITION COMPRISING ETHER LIPID | CAMURUS AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| EP-1663468-A1 | METHOD FOR LOADING AMPHIPHILE PARTICLES WITH ACTIVE AGENTS | CAMURUS AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1660227-A1 | METHOD FOR IMPROVING THE PROPERTIES OF AMPHIPHILE PARTICLES | CAMURUS AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005046642-A1 | COMPOSITIONS OF LIPIDS AND CATIONIC PEPTIDES | CAMURUS AB (SE) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005027976-A2 | COMPOSITION COMPRISING ETHER LIPID | CAMURUS AB (SE) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005014162-A1 | METHOD FOR IMPROVING THE PROPERTIES OF AMPHIPHILE PARTICLES | CAMURUS AB (SE) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014163-A1 | METHOD FOR LOADING AMPHIPHILE PARTICLES WITH ACTIVE AGENTS | CAMURUS AB (SE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231374-A1 | Composition Comprising Ether Lipid | ABHD16A, PHOSPHO1, LIPA | BBOX1 3744/4885LAP3 1736/4885FDPS 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.